BORA PHARMACEUTICALS LTD (6472) — Cash Flow Quality Index
BORA PHARMACEUTICALS LTD (6472) has a Cash Flow Quality Index of 2.98x as of December 2025. Operating cash flow of NT$1.17 Billion exceeds net income of NT$394.37 Million, indicating high earnings quality where cash backs reported profits. Also explore BORA PHARMACEUTICALS LTD (6472) total assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BORA PHARMACEUTICALS LTD Cash Flow Quality Index (2019–2025)
Historical Cash Flow Quality Index for BORA PHARMACEUTICALS LTD across 7 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check BORA PHARMACEUTICALS LTD (6472) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for BORA PHARMACEUTICALS LTD (2019–2025)
Year-by-year earnings quality comparison for BORA PHARMACEUTICALS LTD. For live market cap and the full company financial profile, see BORA PHARMACEUTICALS LTD market cap and net worth.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.97x | NT$4.24 Billion | NT$4.38 Billion | ▲ +388.9% |
| 2024 | 0.20x | NT$980.81 Million | NT$4.95 Billion | ▼ -82.6% |
| 2023 | 1.14x | NT$4.61 Billion | NT$4.06 Billion | ▲ +3.9% |
| 2022 | 1.09x | NT$2.01 Billion | NT$1.84 Billion | ▼ -9.5% |
| 2021 | 1.21x | NT$1.24 Billion | NT$1.02 Billion | ▲ +304.4% |
| 2020 | 0.30x | NT$177.79 Million | NT$595.40 Million | ▼ -60.7% |
| 2019 | 0.76x | NT$231.77 Million | NT$305.03 Million | — |